Cargando…
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Toll-like receptors (TLRs) have first been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded RNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLRs have also been...
Autores principales: | Vacchelli, Erika, Galluzzi, Lorenzo, Eggermont, Alexander, Fridman, Wolf Hervé, Galon, Jerome, Sautès-Fridman, Catherine, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489745/ https://www.ncbi.nlm.nih.gov/pubmed/23162757 http://dx.doi.org/10.4161/onci.20931 |
Ejemplares similares
-
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012) -
Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial Watch: Adoptive cell transfer immunotherapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012) -
Trial watch: Peptide vaccines in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012) -
Trial watch: Dendritic cell-based interventions for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)